WO2002043567A3 - A method of treating cancer - Google Patents

A method of treating cancer Download PDF

Info

Publication number
WO2002043567A3
WO2002043567A3 PCT/US2001/044579 US0144579W WO0243567A3 WO 2002043567 A3 WO2002043567 A3 WO 2002043567A3 US 0144579 W US0144579 W US 0144579W WO 0243567 A3 WO0243567 A3 WO 0243567A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating cancer
methods
glucocorticoid
relates
psa conjugate
Prior art date
Application number
PCT/US2001/044579
Other languages
French (fr)
Other versions
WO2002043567A2 (en
Inventor
Siu-Long Yao
Original Assignee
Merck & Co Inc
Siu-Long Yao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Siu-Long Yao filed Critical Merck & Co Inc
Priority to JP2002545554A priority Critical patent/JP2004517076A/en
Priority to US10/433,596 priority patent/US20040058857A1/en
Priority to CA000000003A priority patent/CA2430239A1/en
Priority to AU2002239368A priority patent/AU2002239368A1/en
Publication of WO2002043567A2 publication Critical patent/WO2002043567A2/en
Publication of WO2002043567A3 publication Critical patent/WO2002043567A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a glucocorticoid, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least one PSA conjugate and at least one glucocorticoid. The invention also relates to methods of preparing such compositions.
PCT/US2001/044579 2000-12-01 2001-11-29 A method of treating cancer WO2002043567A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002545554A JP2004517076A (en) 2000-12-01 2001-11-29 How to treat cancer
US10/433,596 US20040058857A1 (en) 2001-11-29 2001-11-29 Method of treating cancer
CA000000003A CA2430239A1 (en) 2000-12-01 2001-11-29 A method of treating cancer
AU2002239368A AU2002239368A1 (en) 2000-12-01 2001-11-29 A method of treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25069400P 2000-12-01 2000-12-01
US60/250,694 2000-12-01

Publications (2)

Publication Number Publication Date
WO2002043567A2 WO2002043567A2 (en) 2002-06-06
WO2002043567A3 true WO2002043567A3 (en) 2002-10-17

Family

ID=22948771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044579 WO2002043567A2 (en) 2000-12-01 2001-11-29 A method of treating cancer

Country Status (4)

Country Link
JP (1) JP2004517076A (en)
AU (1) AU2002239368A1 (en)
CA (1) CA2430239A1 (en)
WO (1) WO2002043567A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027988A2 (en) * 2006-08-31 2008-03-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US5476842A (en) * 1991-11-04 1995-12-19 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6083936A (en) * 1999-01-25 2000-07-04 Sri International Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US5476842A (en) * 1991-11-04 1995-12-19 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6083936A (en) * 1999-01-25 2000-07-04 Sri International Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use

Also Published As

Publication number Publication date
CA2430239A1 (en) 2002-06-06
JP2004517076A (en) 2004-06-10
WO2002043567A2 (en) 2002-06-06
AU2002239368A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2002092004A8 (en) Use of hmg fragment as anti-inflammatory agents
WO2002002565A3 (en) Glucocortiocoid-selective antiinflammatory agents
EP1355563A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
WO2002016429A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002236986A1 (en) Systems, methods, and compositions for achieving closure of vascular puncture sites
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2003047558A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2000066528A3 (en) Quinones for treatment of diseases
AU2002367023A1 (en) Compositions and methods for treating heart failure
WO2002016602A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002365057A1 (en) Compositions and methods for treating heart failure
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2002043567A3 (en) A method of treating cancer
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001068066A3 (en) A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001987121

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002239368

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2430239

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10433596

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002545554

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001987121

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642